Prof Saul Faust, co-study leader at the University of Southampton and a consultant paediatrician, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”
Be the first to comment